

CADTH RAPID RESPONSE REPORT: SUMMARY OF ABSTRACTS

Hybrid Closed Loop Insulin Delivery Systems: Clinical Effectiveness

Service Line:	Rapid Response Service
Version:	1.0
Publication Date:	September 17, 2019
Report Length:	7 Pages

Authors: Kendra Brett, Melissa Walter

Cite As: Hybrid Closed Loop Insulin Delivery Systems: Clinical Effectiveness Ottawa: CADTH; 2019 Sept. (CADTH rapid response report: summary of abstracts).

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada's provincial or territorial governments, other CADTH funders, or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Questions or requests for information about this report can be directed to requests@cadth.ca

Research Question

What is the clinical effectiveness of hybrid closed-loop insulin delivery systems in patients with type 1 diabetes?

Key Findings

Three randomized controlled trials were identified regarding the clinical effectiveness of hybrid closed-loop insulin delivery systems in patients with type 1 diabetes.

Methods

A limited literature search was conducted by an information specialist on key resources including MEDLINE, the Cochrane Library, the University of York Centre for Reviews and Dissemination (CRD) databases, the websites of Canadian and major international health technology agencies, as well as a focused Internet search. The search strategy was comprised of both controlled vocabulary, such as the National Library of Medicine's MeSH (Medical Subject Headings), and keywords. The main search concepts were hybrid closed-loop insulin delivery systems and diabetes Type 1 and Type 3c. No filters were applied to limit the retrieval by study type. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2003 and August 29, 2019. Internet links were provided, where available.

Selection Criteria

One reviewer screened citations and selected studies based on the inclusion criteria presented in Table 1.

Table 1: Selection Criteria

Population	Patients with insulin-dependent type 1 diabetes Subgroup of interest: patients with type 3c diabetes
Intervention	Hybrid closed-loop insulin delivery systems (e.g., Medtronic MiniMed 670G, Tandem "Control-IQ")
Comparator	Sensor augmented pumps (SAPs); continuous glucose monitoring (CGM); flash glucose monitors (FGMs); closed loops, open loops, hybrid loops; artificial pancreas; self monitoring blood glucose (SMBG); continuous insulin infusion (i.e., insulin pump); multiple daily insulin injections (MDII); any combinations of interventions listed above (e.g., pump plus CGM, pump plus SMBG)
Outcomes	Clinical effectiveness, including: time-in-range, glycated hemoglobin, number of hypoglycemic events requiring assistance, diabetic ketoacidosis, health status (i.e., EuroQol 5D score), hypoglycemia fear survey overall score, and diabetes treatment satisfaction questionnaire overall score

Study Designs

Health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, non-randomized studies

Results

Rapid Response reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are presented first. These are followed by randomized controlled trials and non-randomized studies.

Three randomized controlled trials^{1,2,3} were identified regarding the clinical effectiveness of hybrid closed-loop insulin delivery systems in patients with type 1 diabetes. No relevant health technology assessments, systematic reviews, meta-analyses, or non-randomized studies were identified.

Additional references of potential interest are provided in the appendix.

Overall Summary of Findings

Two randomized controlled trials^{1,2} were identified regarding the clinical effectiveness of the Tandem Control-IQ artificial pancreas system as compared with a sensor augmented pump in adolescents and children with type 1 diabetes. Both studies,^{1,2} found that children and adolescents randomized to the Tandem Control-IQ artificial pancreas system had significantly better time-in-range (70-180 mg/dL) and significantly lower average glucose level, and no difference in hypoglycemia exposure compared to those randomized to a sensor augmented pump. One randomized controlled trial³ was identified regarding the clinical effectiveness of the Medtronic MiniMed 670G hybrid closed-loop system as compared to the Medtronic MiniMed 530G with threshold suspend in patients with type 1 diabetes at a diabetes camp, although the Minimed 670G was not identified by that name in the publication. This study³ found no difference in time-in-range (70-180 mg/dL) or mean glucose level between the groups. In conclusion, the Tandem Control-IQ artificial pancreas system may provide better glycemic control than a sensor augmented pump in pediatric patients with type 1 diabetes, and the Minimed 670G may not provide improved glucose control compared to a sensor augmented pump.

References Summarized

Health Technology Assessments

No literature identified.

Systematic Reviews and Meta-analyses

No literature identified.

Randomized Controlled Trials

1. Ekhlaspour L, Forlenza GP, Chernavsky D, et al. Closed loop control in adolescents and children during winter sports: use of the Tandem Control-IQ AP system. *Pediatr Diabetes*. 2019 Sep;20(6):759-768.
[PubMed: PM31099946](#)

2. Forlenza GP, Ekhlaspour L, Breton M, et al. Successful at-home use of the Tandem Control-IQ artificial pancreas system in young children during a randomized controlled trial. *Diabetes Technol Ther*. 2019 Apr;21(4):159-169.
[PubMed: PM30888835](#)
3. Ly TT, Roy A, Grosman B, et al. Day and night closed-loop control using the integrated Medtronic hybrid closed-loop system in type 1 diabetes at diabetes camp. *Diabetes Care*. 2015 Jul;38(7):1205-1211.
[PubMed: PM26049550](#)

Non-Randomized Studies

No literature identified.

Appendix — Further Information

Randomized Controlled Trials

Study Protocols

4. de Bock M, McAuley SA, Abraham MB, et al. Effect of 6 months hybrid closed-loop insulin delivery in young people with type 1 diabetes: a randomised controlled trial protocol. *BMJ Open*. 2018 Aug;8(8):e020275.
[PubMed: PM30104309](#)
5. McAuley SA, de Bock MI, Sundararajan V, et al. Effect of 6 months of hybrid closed-loop insulin delivery in adults with type 1 diabetes: a randomised controlled trial protocol. *BMJ Open*. 2018 Jun;8(6):e020274.
[PubMed: PM29886443](#)

Alternative Comparator

6. Paldus B, Lee MH, Jones HM, et al. Glucose control using a standard versus an enhanced hybrid closed loop system: a randomized crossover study. *Diabetes Technol Ther*. 2019 Jan;21(1):56-58.
[PubMed: PM30620641](#)

Non-Randomized Studies

Alternative Comparator

7. Stone MP, Agrawal P, Chen X, et al. Retrospective analysis of 3-month real-world glucose data after the MiniMed 670G system commercial launch. *Diabetes Technol Ther*. 2018 Oct;20(10):689-692.
[PubMed: PM30160523](#)
8. Cordero TL, Garg SK, Brazg R, et al. The effect of prior continuous glucose monitoring use on glycemic outcomes in the pivotal trial of the MiniMed™ 670G hybrid closed-loop system. *Diabetes Technol Ther*. 2017 Dec;19(12):749-752.
[PubMed: PM29148821](#)

No Comparator or Control Group

9. de Bock M, Dart J, Roy A, et al. Exploration of the performance of a hybrid closed loop insulin delivery algorithm that includes insulin delivery limits designed to protect against hypoglycemia. *J Diabetes Sci Technol*. 2017 Jan;11(1):68-73.
[PubMed: PM27621143](#)

Uncontrolled Before-and-After Studies

10. Faulds ER, Zappe J, Dungan KM. Real-world implications of hybrid close loop (HCL) insulin delivery system. *Endocr Pract*. 2019 May;25(5):477-484.

[PubMed: PM30865545](#)

11. Forlenza GP, Pinhas-Hamiel O, Liljenquist DR, et al. Safety evaluation of the MiniMed 670G system in children 7-13 years of age with type 1 diabetes. *Diabetes Technol Ther.* 2019 Jan;21(1):11-19.

[PubMed: PM30585770](#)

12. Salehi P, Roberts AJ, Kim GJ. Efficacy and safety of real-life usage of MiniMed 670G automode in children with type 1 diabetes less than 7 years old. *Diabetes Technol Ther.* 2019 Aug;21(8):448-451.

[PubMed: PM31166801](#)

13. Messer LH, Forlenza GP, Sherr JL, et al. Optimizing hybrid closed-loop therapy in adolescents and emerging adults using the MiniMed 670G system. *Diabetes Care.* 2018 Apr;41(4):789-796.

[PubMed: PM29444895](#)

14. Garg SK, Weinzimer SA, Tamborlane WV, et al. Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. *Diabetes Technol Ther.* 2017 Mar;19(3):155-163.

[PubMed: PM28134564](#)

15. Ly TT, Weinzimer SA, Maahs DM, et al. Automated hybrid closed-loop control with a proportional-integral-derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance. *Pediatr Diabetes.* 2017 Aug;18(5):348-355.

[PubMed: PM27191182](#)

Case Reports

16. Brown S, Raghinaru D, Emory E, Kovatchev B. First look at Control-IQ: a new-generation automated insulin delivery system. *Diabetes Care.* 2018 Dec;41(12):2634-2636.

[PubMed: PM30305346](#)

17. Petrovski G, Al Khalaf F, Hussain K, Campbell J. Optimizing a hybrid closed loop system in type 1 diabetes: a case report. *Diabetes Ther.* 2018 Oct;9(5):2173-2177.

[PubMed: PM30030688](#)

Review Articles

18. MiniMed 670G hybrid closed-loop system (Medtronic plc.) for managing type 1 diabetes. Plymouth Meeting (PA): ECRI Institute; 2016: www.ecri.org. Accessed 2019 Sep 16.